Expand all sections

Veliparib

Extended indication Non-squamous non-small cell lung cancer (NSCLC), 1L.
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Veliparib
Domain Oncology and Hematology
Main indication Lung cancer
Extended indication Non-squamous non-small cell lung cancer (NSCLC), 1L.
Manufacturer Abbvie
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Particularity New medicine
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

Patient volume

< 811

Market share is generally not included unless otherwise stated.
References NKR; Pakketadvies Atezolizumab
Additional remarks NKR 2016: 9.289 diagnoses NSCLC, stadium 3 en 4. 35% niet-plaveiselcel. 60% onvangt eerstelijnsbehandeling, waarvan 50% chemotherapie. Dit komt neer op een totaal van 811 patiënten. Hiervan zal een klein deel mogelijk worden behandeld met Veliparib vanwege de behandelopties met immuuntherapie.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.